Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 5 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysLast 90 days, $4.50M in total
- 5
- Insider sellsLast 90 days, $279.0K in total
- 2
- 13F holdersQ2 2026, +30 vs. previous quarter
- 162
- 13F valueReported value at the end of Q2 2026
- $1.36B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding INBX, Q2 2026
1 superinvestor reports holding Inhibrx Biosciences, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.3%
Inhibrx Biosciences, Inc.'s share of the portfolio
- Shares
- 1,123,929
- Value
- $106.5M
Latest insider trades
Open-market purchases and sales by Inhibrx Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)4:59 PM ET | Sep 23 | Same day | Kayyem Jon FaizDirector | PPurchase | +5.00K | $100.00 | +$500.0K | +1.2%434.4K after | |
| Sep 17, 2026 (view filing)5:46 PM ET | Sep 16 | 1 day | Kayyem Jon FaizDirector | PPurchase | +5.00K | $100.00 | +$500.0K | +1.2%429.4K after | |
| Sep 15, 2026 (view filing)5:52 PM ET | Sep 11-15 | 4 days | Manhard KimberlyDirector | SSale | −1.50K | $109.03 | −$163.5K | −16.7%7.50K after | 3 lots |
| Sep 10, 2026 (view filing)7:06 PM ET | Sep 8-9 | 2 days | Manhard KimberlyDirector | SSale | −1.00K | $115.47 | −$115.5K | −10.0%9.00K after | 2 lots |
| Sep 8, 2026 (view filing)5:23 PM ET | Sep 8 | Same day | Kayyem Jon FaizDirector | PPurchase | +5.00K | $113.52 | +$567.6K | +1.2%424.4K after | |
| Sep 8, 2026 (view filing)4:26 PM ET | Sep 8 | Same day | Forsyth DouglasDirector | PPurchase | +2.50K | $114.65 | +$286.6K | +1.1%227.1K after | |
| Sep 8, 2026 (view filing)4:04 PM ET | Sep 8 | Same day | Lappe MarkChief Executive Officer | PPurchase | +25.0K | $105.82 | +$2.65M | +3.5%730.5K after | 6 lots |
| Oct 9, 2025 (view filing)4:41 PM ET | Oct 7 | 2 days | Viking Global Investors LP and 7 others10% Owner | SSale | −350.0K | $32.25 | −$11.3M | −77.3%102.9K after | 3 lots |
| Nov 22, 2024 (view filing) | Nov 19-20 | 3 daysLate | Kayyem Jon FaizDirector | PPurchase | +107.2K | $14.22 | +$1.52M | New position69.8K after | 4 lots |
| Oct 7, 2024 (view filing) | Oct 3 | 4 days | Vuori Kristiina MDDirector | PPurchase | +6.67K | $15.00 | +$100.0K | +48.4%20.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Inhibrx Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 1,308,051 | $123.9M | 0.01% | +44,973+3.6% | Added |
| Perceptive Advisors LLC | 1,297,763 | $123.0M | 1.91% | −144,944−10.0% | Reduced |
| Sanofi | 1,157,926 | $109.7M | 20.54% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 1,123,929 | $106.5M | 0.30% | −313,776−21.8% | Reduced |
| HighTower Advisors, LLC | 870,551 | $82.5M | 0.08% | +3510.0% | Added |
| Bank of America Corp | 841,141 | $79.7M | 0.01% | +808,458+2,473.6% | Added |
| BlackRock, Inc. | 825,972 | $78.3M | 0.00% | +27,074+3.4% | Added |
| Schonfeld Strategic Advisors LLC | 697,586 | $66.1M | 0.35% | +442,759+173.7% | Added |
| State Street Corp | 640,458 | $60.7M | 0.00% | +89,613+16.3% | Added |
| Vanguard Capital Management LLC | 492,477 | $46.7M | 0.00% | +6,055+1.2% | Added |